Arkın ACAR, Zekiye AYDOĞDU, Soner GÜRSOY, Şeyda ÖRS KAYA, Kenan Can CEYLAN, Sadık YALDIZ, Demet YALDIZ

Prognostic Effects of Predominant Histologic Subtypes in Resected Pulmonary Adenocarcinomas

Background: Predominant histologic subtypes have been reported as predictors of survival of patients with pulmonary adenocarcinoma.Aims: To evaluate the predictive value of histologic classification in resected lung adenocarcinoma using the classification systems proposed by the International Association for the Study of Lung Cancer, American Thoracic Society, European Respiratory Society, and World Health Organization (2015).Study Design: Cross-sectional study.Methods: The histologic classification of a large cohort of 491 patients with resected lung adenocarcinoma (stages I-III) was retrospectively analyzed. The tumors were classified according to their predominant component (lepidic, acinar, papillary, solid, micropapillary, and mucinous), and their predictive values were assessed for clinicopathologic characteristics and overall survival.Results: The patient cohort comprised 158 (32.2%) patients with solid predominant, 150 (30.5%) with acinar predominant, 80 (16.3%) with papillary predominant, 75 (15.3%) with lepidic predominant, 22 (4.5%) with mucinous, and 5 (1.0%) with micropapillary subtype, and 1 (0.2%) with adenocarcinoma in situ. Overall 5-year survival of 491 patients was found to be 51.8%. Patients with lepidic, acinar, and mucinous adenocarcinoma had 70.9%, 59.0%, and 66.6% 5-year survival, respectively, and there was no statistically significant difference between them. Whereas patients with solid, papillary, and micropapillary predominant adenocarcinoma had 41.0%, 40.5%, and 0.0% 5-year survival, respectively. Compared to other histologic subtypes, patients with solid and papillary predominant adenocarcinoma had significantly lower survival than those with lepidic (p

PDF

___

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International Association for the Study of Lung Cancer/ American Thoracic Society/ European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011;6:244-85.
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. Fourth edition ed. WHO Classification of Tumours. Geneva: IARC, WHO Press, 2015.
Little AG, Rusch VW, Bonner JA, Gaspar LE, Green MR, Webb WR, et al. Patterns of surgical care of lung cancer patients. Ann Thorac Surg 2005;80:2051-6.
Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: Prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011;24:653-64.
Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, et al. The novel histologic International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012;30:1438-46.
Urer HN, Kocaturk CI, Gunluoglu MZ, Arda N, Bedirhan MA, Fener N, et al. Relationship between lung adenocarcinoma histological subtype and patient prognosis. Ann Thorac Cardiovasc Surg 2014;20:12-8.
Zhang Y, Li J, Wang R, Li Y, Pan D, Cai D, et al. The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma. Sci Rep 2014;4:7163.
Russell PA, Wright GM. Predominant histologic subtype in lung adenocarcinoma predicts benefit from adjuvant chemotherapy in completely resected patients: discovery of a holy grail? Ann Transl Med 2016;4:16.
Hung JJ, Yeh YC, Jeng WJ, Wu KJ, Huang BS, Wu YC, et al. Predictive Value of the International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society Classification of Lung Adenocarcinoma in Tumor Recurrence and Patient Survival. J Clin Oncol 2014;32:2357-64.
Ohtaki Y, Yoshida J, Ishii G, Aokage K, Hishida T, Nishimura M, et al. Prognostic Significance of a Solid Component in Pulmonary Adenocarcinoma. Ann Thorac Surg 2011;91:1051-7.
Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival? A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011;6:1496-504.
Dacic S. Pros: the present classification of mucinous adenocarcinomas of the lung. Transl Lung Cancer Res 2017;6:230-3.
Wislez M, Antoine M, Baudrin L, Poulot V, Neuville A, Pradere M, et al. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib. Lung Cancer 2010;68:185-91. Shim HS, Kenudson M, Zheng Z, Liebers M, Cha YJ, Hoang HQ, et et al. Unique genetic and survival characteristics of invasive mucinous adenocarcinoma of the lung. J Thorac Oncol 2015;10:1156-62.
Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations. Analysis of 440 Japanese patients. J Thorac Oncol 2013;8:52-61.
Tsubokawa N, Mimae T, Sasada S, Yoshiya T, Mimura T, Murakami S, et al. Negative prognostic influence of micropapillary pattern in stage IA lung adenocarcinoma. Eur J Cardiothorac Surg 2016;49:293-9.